Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael C Haffner

Showing results (121-130 of 169) with videos related to

Pageof 17
Sort By:
Cancer Research Communications|November 7, 2022
Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterationsRadhika A Patel, Ilsa Coleman, Martine P Roudier, et al.
Prostate Cancer and Prostatic Diseases|December 23, 2022
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancerMichael T Schweizer, Roman Gulati, Todd Yezefski, et al.
Cancer Research|May 25, 2019
Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic ProgressionRobert M Hughes, Brian W Simons, Hamda Khan, et al.
Scientific Reports|April 8, 2016
Image-based computational quantification and visualization of genetic alterations and tumour heterogeneityQing Zhong, Jan H Rüschoff, Tiannan Guo, et al.
JCI Insight|May 23, 2022
Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistromeXintao Qiu, Lisha G Brown, Jennifer L Conner, et al.
The Journal of Clinical Investigation|April 1, 2026
Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancersAlec Paschalis, Ines Figueiredo, Denisa Bogdan, et al.
European Urology Oncology|February 7, 2025
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after <sup>177</sup>Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair GenesRuben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, et al.
The American Journal of Pathology|March 27, 2018
Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate CancerMichael C Haffner, Gunes Guner, Diana Taheri, et al.
Cancer Cell|November 3, 2023
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancerJessica E Hawley, Aleksandar Z Obradovic, Matthew C Dallos, et al.
JCI Insight|December 8, 2021
Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancerNavonil De Sarkar, Sayan Dasgupta, Payel Chatterjee, et al.
Pageof 17

Showing results (121-130 of 169) with videos related to

Sort By:
Pageof 17
Cancer Research Communications|November 7, 2022
Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterationsRadhika A Patel, Ilsa Coleman, Martine P Roudier, et al.
Prostate Cancer and Prostatic Diseases|December 23, 2022
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancerMichael T Schweizer, Roman Gulati, Todd Yezefski, et al.
Cancer Research|May 25, 2019
Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic ProgressionRobert M Hughes, Brian W Simons, Hamda Khan, et al.
Scientific Reports|April 8, 2016
Image-based computational quantification and visualization of genetic alterations and tumour heterogeneityQing Zhong, Jan H Rüschoff, Tiannan Guo, et al.
JCI Insight|May 23, 2022
Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistromeXintao Qiu, Lisha G Brown, Jennifer L Conner, et al.
The Journal of Clinical Investigation|April 1, 2026
Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancersAlec Paschalis, Ines Figueiredo, Denisa Bogdan, et al.
European Urology Oncology|February 7, 2025
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after <sup>177</sup>Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair GenesRuben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, et al.
The American Journal of Pathology|March 27, 2018
Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate CancerMichael C Haffner, Gunes Guner, Diana Taheri, et al.
Cancer Cell|November 3, 2023
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancerJessica E Hawley, Aleksandar Z Obradovic, Matthew C Dallos, et al.
JCI Insight|December 8, 2021
Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancerNavonil De Sarkar, Sayan Dasgupta, Payel Chatterjee, et al.
Pageof 17